Cell therapeutics' pixuvri approved in european union as monotherapy to treat adult patients with multiply relapsed or refractory aggressive non-hodgkin b-cell lymphomas
Cell Therapeutics, 05/11/2012
Cell Therapeutics, Inc. announced that it has received conditional marketing authorization from the European Commission ("EC") for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non–Hodgkin B–cell lymphomas ("NHL"). Pixuvri is the first approved treatment in the European Union ("EU") in this patient setting.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.